Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in CFRD
NCT06149793Phase 3Active, not recruiting
- Sponsor
- University of Minnesota
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in cystic fibrosis-related diabetes (CFRD), sponsored by University of Minnesota. Started Jan 2024; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
cystic fibrosis-related diabetes (CFRD)
Beyond the preview
Go deeper on NCT06149793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149793.